NASDAQ: MNOV - MediciNova, Inc.

Lønnsomhet i seks måneder: +47.86%
Sektor: Healthcare

Kampanjeplan MediciNova, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.

flere detaljer
The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2005-02-08
ISIN US58468P2065
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.medicinova.com
Цена ао 1.36
Prisendring per dag: +6.15% (1.95)
Prisendring per uke: -4.61% (2.17)
Prisendring per måned: +2.99% (2.01)
Prisendring over 3 måneder: +8.38% (1.91)
Prisendring over seks måneder: +47.86% (1.4)
Prisendring per år: +38% (1.5)
Prisendring over 3 år: -24.45% (2.74)
Prisendring over 5 år: -71.68% (7.31)
Prisendring over 10 år: 0% (2.07)
Prisendring siden begynnelsen av året: -10% (2.3)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 71.61 1
P/BV 1.15 9
P/E 0 0
EV/EBITDA -2.11 0
Total: 4.63

Effektivitet

Navn Betydning Karakter
ROA, % -12.93 0
ROE, % -13.74 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0219 10
Total: 6.2

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 24.6 4
Lønnsomhet Ebitda, % -29.43 0
Lønnsomhet EPS, % -41.73 0
Total: 0.8
Flere detaljer

Institusjoner Volum Dele, %
Essex Woodlands Management Inc. 1105941 2.25
Blackrock Inc. 699642 1.43
Vanguard Group Inc 623333 1.27
Citigroup Inc. 447957 0.91
Geode Capital Management, LLC 435733 0.89
Renaissance Technologies, LLC 174100 0.35
Bank of America Corporation 167959 0.34
State Street Corporation 157198 0.32
Northern Trust Corporation 153556 0.31
Dimensional Fund Advisors LP 152530 0.31

ETF Dele, % Lønnsomhet for året, % Utbytte, %
iShares Micro-Cap ETF 0.02281 17.09 1.54048



Veileder Stillingstittel Betaling Fødselsår
Dr. Yuichi Iwaki M.D., Ph.D. Co-Founder, President, CEO & Executive Director 907.26k 1950 (75 år)
Dr. Kazuko Matsuda M.D., M.P.H., Ph.D. Chief Medical Officer & Director 649.05k 1966 (59 år)
Mr. Jason J. Kruger CPA CFO & Principal Financial Officer N/A 1978 (47 år)
Dr. David H. Crean M.B.A., Ph.D. Chief Business Officer N/A 1965 (60 år)
Mr. John O'Neil CPA Controller

Adresse: United States, La Jolla. CA, 4275 Executive Square - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.medicinova.com